Drew Barrymore Women's HRT: The Evidence Base Behind That Protocol

What the Public Record Can and Cannot Show

CBS News reported in March 2023 that Barrymore identified herself as being in perimenopause and, at that time, said she had declined hormone therapy because the recommendation felt premature. [4] AARP later reported in November 2025 that she described having tried hormone therapy and experiencing a difficult period of trial and error. [5] The later report updates the public timeline, but neither source identifies a product, dose, route, duration, laboratory result, or complete clinical outcome.

Clinical evidence can explain what clinicians consider when evaluating menopausal hormone therapy, but it cannot show that a general hormone guideline matches Barrymore's private care. The public timeline and the medical evidence that applies to patients generally are separate bodies of information.

The Evidence Base for Menopause Hormone Therapy

The Menopause Society's 2022 position statement remains a central source for systemic hormone therapy. It states that hormone therapy is the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause and can prevent bone loss and fracture in appropriate candidates. [1] The statement also emphasizes individualization by age, time since menopause, symptom burden, personal risk factors, and treatment goals.

For many healthy people younger than 60 or within 10 years of menopause onset who have bothersome hot flashes or night sweats and no contraindications, the benefit-risk balance may be favorable. For someone older, farther from menopause onset, or with higher baseline cardiovascular, thrombotic, breast cancer, or liver risk, the same therapy may carry a different risk profile. The original Women's Health Initiative estrogen-plus-progestin trial and a later Cochrane review both show why benefits and harms must be evaluated by indication, formulation, age, and baseline risk. [7,10]

Estrogen, Progesterone, and Route

Systemic estrogen treats vasomotor symptoms. If a person has an intact uterus, systemic estrogen is typically paired with a progestogen to reduce the risk of endometrial hyperplasia and cancer. People without a uterus may not need that endometrial protection, but they still need individualized review of cardiovascular, thrombotic, breast, migraine, liver, and medication-interaction history.

Route matters, but not as a celebrity shortcut. Transdermal estradiol avoids first-pass hepatic metabolism and may be preferred in some patients with risk factors, while oral estrogen may be reasonable for others. In the observational ESTHER study, oral but not transdermal estrogen was associated with increased venous-thromboembolism risk; that result informs route discussions but does not replace individual assessment. [6] The choice also depends on symptoms, preference, cost, coverage, skin tolerability, and clinician judgment.

What Testosterone Evidence Actually Supports

The global consensus position statement does not support a generalized "women's HRT stack." Its central boundary is narrow: the only evidence-based indication for testosterone therapy in women is treatment of postmenopausal women diagnosed with hypoactive sexual desire disorder after a biopsychosocial assessment. [2] The consensus does not support testosterone for general energy, celebrity-style optimization, mood, cognition, body composition, or unsupervised anti-aging use.

Perimenopause Is Not Diagnosed by Internet Pattern Matching

Perimenopause is a reproductive transition marked by cycle variability and symptoms that can include hot flashes, sleep disruption, mood changes, migraine shifts, and genitourinary symptoms. The STRAW+10 staging framework helps clinicians classify reproductive aging, but symptoms overlap with thyroid disease, anemia, depression, medication effects, pregnancy, sleep apnea, and other conditions. [3]

That overlap prevents a public story from establishing a diagnosis. A person's own disclosure can document what they said about their health, but further diagnostic claims require reliable medical documentation and cannot be inferred from common symptoms alone.

What a Real Evaluation Looks Like

A clinician evaluating menopausal symptoms typically reviews menstrual history, pregnancy possibility when relevant, vasomotor and sleep symptoms, mood history, migraine, clotting history, cardiovascular risk, breast cancer history, uterine status, medications, tobacco use, blood pressure, and patient goals. Lab testing is not always necessary to diagnose typical perimenopause in midlife, but targeted testing may be appropriate when symptoms are atypical or another diagnosis is plausible.

Treatment choices may include lifestyle measures, nonhormonal medications, vaginal therapies, systemic estrogen with appropriate progestogen protection, and referral for complex risk histories. Shared decision-making is the point. The right question is not "What celebrity protocol should I copy?" but "What symptoms am I treating, what risks do I carry, and what options are evidence-based for my situation?" Our broader hormone therapy guide covers the clinical care pathway without relying on celebrity comparisons.

Mood and sleep deserve their own assessment. One randomized trial found that transdermal estradiol plus intermittent micronized progesterone reduced the development of clinically significant depressive symptoms during the menopause transition in the studied population. [8] Long-term follow-up of the Women's Health Initiative trials did not find a difference in all-cause mortality between hormone-therapy and placebo groups, but mortality is only one part of the benefit-risk decision. [9] Neither finding identifies Barrymore's treatment or predicts an individual's response.

Bottom Line

The public record shows that Barrymore discussed perimenopause in 2023 and later described a hormone-therapy experience, but it does not reveal a reproducible protocol. The clinical evidence is broader: systemic hormone therapy is effective for vasomotor symptoms in appropriate candidates; progestogen decisions depend on uterine status; and testosterone has a narrow evidence-based indication.